- Home
- RMCO vs TLPH Comparison
RMCO vs TLPH Comparison
Compare RMCO & TLPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RMCO
- TLPH
- Stock Information
- Founded
- RMCO 2021
- TLPH 2005
- Country
- RMCO United States
- TLPH United States
- Employees
- RMCO N/A
- TLPH N/A
- Industry
- RMCO Multi-Sector Companies
- TLPH Biotechnology: Pharmaceutical Preparations
- Sector
- RMCO Miscellaneous
- TLPH Health Care
- Exchange
- RMCO Nasdaq
- TLPH Nasdaq
- Market Cap
- RMCO 45.7M
- TLPH 11.1M
- IPO Year
- RMCO N/A
- TLPH 2011
- Fundamental
- Price
- RMCO $2.96
- TLPH $1.18
- Analyst Decision
- RMCO Buy
- TLPH Strong Buy
- Analyst Count
- RMCO 1
- TLPH 1
- Target Price
- RMCO N/A
- TLPH $6.00
- AVG Volume (30 Days)
- RMCO 162.9K
- TLPH 469.2K
- Earning Date
- RMCO 11-14-2025
- TLPH 11-12-2025
- Dividend Yield
- RMCO 0.34%
- TLPH N/A
- EPS Growth
- RMCO N/A
- TLPH N/A
- EPS
- RMCO N/A
- TLPH N/A
- Revenue
- RMCO $2,641,171.00
- TLPH $27,000.00
- Revenue This Year
- RMCO N/A
- TLPH N/A
- Revenue Next Year
- RMCO N/A
- TLPH $14,533.26
- P/E Ratio
- RMCO N/A
- TLPH N/A
- Revenue Growth
- RMCO 292.46
- TLPH N/A
- 52 Week Low
- RMCO $0.90
- TLPH $0.38
- 52 Week High
- RMCO $4.76
- TLPH $1.45
- Technical
- Relative Strength Index (RSI)
- RMCO 52.37
- TLPH 62.54
- Support Level
- RMCO $2.80
- TLPH $1.04
- Resistance Level
- RMCO $4.29
- TLPH $1.24
- Average True Range (ATR)
- RMCO 0.54
- TLPH 0.15
- MACD
- RMCO -0.01
- TLPH -0.02
- Stochastic Oscillator
- RMCO 28.00
- TLPH 54.38
About RMCO Royalty Management Holding Corporation
Royalty Management Holding Corp formed to invest or purchase assets that have current or near-term income to provide the company with accretive cash flow from which it can reinvest in new assets or expand cash flow from existing assets. These assets typically are natural resources assets (including real estate and mining permits), patents, intellectual property, and emerging technologies.
About TLPH Talphera Inc.
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.